Relmada Therapeutics

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) diseases. Its lead product candidate, REL-1017, an NMDA receptor antagonist, is in late-stage development as an adjunctive treatment for major depressive disorder.
https://app.dealroom.co/companies/***
https://crunchbase.com/organization/***
https://linkedin.com/company/***

Sergio Traversa Ph.D

CEO and Board Member

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.